What Civica Foundation does

The Civica Foundation is a 501(c)(3) nonprofit organization that serves as the fundraising and philanthropic arm of the broader Civica group, a multi-entity nonprofit pharmaceutical platform. The Foundation's mission is to ensure quality generic medications are available and affordable, and it operationalizes that mission by channeling philanthropic capital into two main program areas: the affordable insulin initiative (supporting CivicaScript's launch of insulin glargine-yfgn at $45/box with a MaxRP of $55, manufactured by Biocon Biologics and branded as CalRx in California) and the Civica Rural Hospital Program, a three-year pilot funded by a $3.2M Helmsley Charitable Trust grant to remove financial barriers for approximately 225 rural and critical access hospitals across nine U.S. states. The Foundation is led by President Todd Shellenberger and operates with 1-10 employees from the Civica headquarters in Lehi, Utah, while the broader Civica platform runs a 140,000 sq ft sterile injectable manufacturing facility in Petersburg, Virginia, a 60+ member hospital network supplying 70+ essential generic medicines to 1,400+ hospitals, and a Federal Supply Schedule contract with the U.S. Department of Veterans Affairs awarded in December 2025.

The Foundation's revenue model is grant-driven rather than commercial: documented inflows include a $3.2M Helmsley grant (May 2026) and a $3M Commonwealth of Virginia grant (2025), with Helmsley having supported the insulin initiative since 2022. The Foundation underwrites the patient-affordability programs that the operating entities (Civica Rx for hospital members; CivicaScript for outpatient generics and biosimilars) then deliver, and it coordinates with more than 25 philanthropic partners, state governments, and patient-advocacy organizations including Breakthrough T1D. Distribution of the Foundation's funded products flows through CivicaScript to U.S. retail pharmacies (including the CalRx channel in California) and through the broader Civica platform's exclusive AmerisourceBergen distribution partnership to hospitals, the VA/DoD via FSS, and the U.S. Strategic National Stockpile.

The Civica Foundation operates within a governance structure dominated by leading U.S. health systems (Mayo Clinic, HCA Healthcare, Kaiser Permanente, CommonSpirit, Trinity Health, Providence, Intermountain, Memorial Hermann, and others) and founding philanthropies (Laura and John Arnold Foundation, Peterson Center on Healthcare, Gary and Mary West Foundation), with the Foundation itself supported by Helmsley, the Commonwealth of Virginia, Blue Cross of Idaho, and additional donors. The organization pursues a nonprofit cost-plus pricing model with equal prices across all members regardless of size, transparent MaxRP QR-coded labeling for outpatient products, and minimum-order commitments that incentivize manufacturers to maintain steady production of shortage-prone essential medicines.

Name

Civica Foundation

Legal name

Civica Foundation

Website

https://civicarx.org

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

The Civica Foundation is a 501(c)(3) nonprofit fundraising arm of the Civica pharmaceutical platform, channeling philanthropic grants into the affordable insulin initiative and the Civica Rural Hospital Program that serves ~225 rural and critical access hospitals across nine U.S. states.

Ownership category

akta.pro rank

Product category

Nonprofit Healthcare Philanthropy / Foundation Grant Programs

NAICS

Grantmaking Foundations (813211), Grantmaking and Giving Services (8132)

SIC

Services-Social Services (8300)

akta.pro primary industry

Private Foundations (BPAGAKAA)

akta.pro secondary industry

Family Offices & Philanthropic Advisors (Grantmaking) (BPAGAKAD)

Keywords

• Nonprofit pharmaceutical foundation
• Rural hospital program
• Affordable insulin initiative
• Philanthropic healthcare grants
• Generic drug access

Headquarters

HQ city

Lehi

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Hospital/health-system membership fees and drug sales: Civica operates on a B2B membership model where hospital systems pay per-bed membership fees and enter market-stabilizing contracts to purchase Civica medications directly. Same cost-plus price offered to all members regardless of hospital size. Used by 60+ members representing 1,400+ hospitals. Annual purchase commitments apply (waived for rural program participants).
2. Outpatient/retail medication sales (via CivicaScript): CivicaScript sells affordable generic and biosimilar medications directly to U.S. pharmacies at single transparent prices (e.g., insulin glargine at $45/box of 5 pens wholesale; ustekinumab-aauz at $985 WAC for 90mg 12-week supply and $575 WAC for 45mg 12-week supply). Pharmacies/health plans recommended to cap consumer prices at no more than $55 for insulin.
3. Philanthropic grants and donations (via Civica Foundation): The Civica Foundation, a 501(c)(3), fosters philanthropic support to manufacture and distribute affordable generic medications. Helmsley Charitable Trust awarded $3.2M for the Rural Hospital Program; Helmsley also supported insulin affordability work since 2022; Commonwealth of Virginia granted $3 million to advance insulin access.
4. Federal/government supply contracts: Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs enables product sales to all VA medical centers and outpatient clinics, plus other federal agencies including the Department of Defense, through the Pharmaceutical Prime Vendor (PPV) program.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

The Civica Foundation is a 501(c)(3) nonprofit organization that operates as the fundraising and philanthropic arm of the broader Civica group. It channels charitable grants and donations into two primary programmatic areas: the Civica Rural Hospital Program, which uses philanthropic funding to cover per-bed membership fees and waive annual purchase commitments for eligible rural and critical access hospitals, and the affordable insulin initiative, which underwrites CivicaScript's launch of low-cost biosimilar insulin and other outpatient biosimilars. The Foundation does not sell products directly; it deploys philanthropic capital to remove financial barriers to essential generic medications.

Product overview

Civica Foundation is the 501(c)(3) fundraising arm of the broader Civica organization, operating as part of a multi-entity nonprofit pharmaceutical platform rather than a single unified product. The Foundation supports two main program areas: (1) the Civica Rural Hospital Program, a three-year pilot designed to remove financial barriers for rural and critical access hospitals to access essential generic injectables through grants from partners such as The Leona M. and Harry B. Helmsley Charitable Trust; and (2) the affordable insulin initiative, which underpins CivicaScript's launch of insulin glargine-yfgn in pre-filled pens at a $45 list price ($55 MaxRP) and ustekinumab-aauz, plus CivicaScript's earlier abiraterone acetate generic for prostate cancer. The Civica Rx parent entity supplies more than 70 essential generic sterile injectable medications to over 1,400 U.S. hospitals through its hospital membership program, and its Petersburg, Virginia manufacturing facility adds domestic fill-finish capacity for vials, syringes, and pen cartridges. CivicaScript serves as the outpatient/retail channel with transparent Maximum Retail Price (MaxRP) labeling. Together, Civica Rx, CivicaScript, and the Civica Foundation form an integrated nonprofit drug-company platform combining hospital-facing essential medicines, outpatient biosimilars, and philanthropic funding — with all program revenue and operations channeled toward ensuring access and affordability rather than profit.

Differentiator

Problem solved

Functional benefit

Products and services

• Civica Rural Hospital Program Three-year pilot program that uses philanthropic grant funding to cover per-bed Civica membership fees and waive annual purchase commitments for eligible rural and critical access hospitals in nine U.S. states, enabling them to access Civica's hospital supply of essential generic injectable medications at no cost.
• Affordable Insulin Initiative Foundation-led initiative that channels philanthropic and state-government funding (Helmsley Charitable Trust, Commonwealth of Virginia, Breakthrough T1D/JDRF, Gary and Mary West Foundation, and others) to support CivicaScript's development and distribution of affordable biosimilar insulin products for U.S. consumers.
• Philanthropic Grant Stewardship and Fundraising Services Core fundraising, donor cultivation, and grant stewardship service of the Civica Foundation as a 501(c)(3) organization, including major-gift and planned-giving programs led by the Foundation President and team to support Civica's mission of ensuring quality generic medications are available and affordable.

Named customers30 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Biocon BiologicscoreOEM/ Whitelabel/ Licensing Partner · 15 October 2025Biocon Biologics manufactures Civica's Insulin Glargine-yfgn product (interchangeable with Lantus®) under its existing U.S. marketing approval. The product is sold by CivicaScript to U.S. pharmacies for $45 per box of five pens (MaxRP $55). Partnership supports Civica's mission to expand affordable insulin access.
• AmerisourceBergencoreChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive distribution partnership established with AmerisourceBergen (announced 2023) for Civica products reaching U.S. hospitals; enables Civica to leverage AmerisourceBergen's distribution infrastructure for its 70+ essential medicines.
• State of California (CalRx Biosimilar Insulin Initiative)coreStrategic or Co-development Partner · 1 January 2023Civica was selected as manufacturing partner for CalRx's Biosimilar Insulin Initiative. Civica insulin glargine carries the CalRx brand in California pharmacies; partnership also covers insulin at maximum recommended retail prices.
• Phlow Corp.coreStrategic or Co-development Partner · 21 January 2021Phlow Corp. partnership to build 120,000 sq ft (later 140,000 sq ft) sterile injectable manufacturing facility in Petersburg, VA. Phlow executed $354M HHS/ASPR/BARDA contract; Civica produces finished dosage forms (vials, syringes) for member hospitals and the U.S. Strategic National Stockpile. Includes co-location with VCU Medicines for All Institute and AMPAC Fine Chemicals.
• Medicines for All Institute at Virginia Commonwealth University (VCU)coreStrategic or Co-development PartnerVCU's Medicines for All Institute collaborates as part of the U.S. government-funded partnership for end-to-end domestic generic drug manufacturing. Co-located at the Petersburg, VA site.
• AMPAC Fine ChemicalscoreStrategic or Co-development PartnerAMPAC Fine Chemicals, also located in Petersburg, VA, is part of the U.S. government-funded partnership with Phlow and VCU for end-to-end domestic generic drug manufacturing.
• Thermo Fisher ScientificcoreStrategic or Co-development PartnerThermo Fisher is one of Civica's contract manufacturing organizations for producing Civica medications as part of Civica's three-pronged product supply strategy (working with FDA-approved manufacturers to produce under Civica's NDC).
• GeneSys Biologics (insulin development partner)coreStrategic or Co-development PartnerGeneSys Biologics is Civica's affordable insulin development partner. Partnership was orchestrated by then-COO Ned McCoy with the plan to bring Civica biosimilar insulins to market beginning in 2024.
• Blue Cross Blue Shield Association (BCBSA)coreGTM or Marketing PartnerBCBSA formed partnership with Civica more than six years ago through InnovateRx LLC (founded in 2020 by 19 Blue Cross Blue Shield Plans and the Federal Employee Program). Partnership aligns Plans around shared goal of expanding access to affordable outpatient generic drugs and biosimilars (including insulin glargine).
• Blue Cross of IdahominorGTM or Marketing PartnerBlue Cross of Idaho represented on Civica's Board of Directors; Drew Hobby serves as Chief Innovation Officer at Blue Cross of Idaho.
• Breakthrough T1D (JDRF)coreGTM or Marketing PartnerBreakthrough T1D (formerly JDRF) has joined with more than 25 other philanthropic partners and the states of California and Virginia to support Civica's development of three commonly prescribed insulin types. CEO Aaron J. Kowalski, Ph.D. is a public advocate for Civica's insulin initiatives.
• groninger and SKANcoreTechnology or Integrationgroninger and SKAN are world-class manufacturing technology partners for Civica's Petersburg, VA plant. Case study (March 22, 2024) documented the partnership on essential medicines manufacturing technology.
• U.S. Department of Health and Human Services (HHS/ASPR/BARDA)coreStrategic or Co-development PartnerU.S. government-funded partnership to expand U.S.-based pharmaceutical manufacturing for COVID-19 response (May 2020). Phlow executed a $354 million HHS/ASPR/BARDA contract. Civica provided 1.6 million doses of critical medicines to the national stockpile for COVID-19 response.
• InnovateRx LLCcoreStrategic or Co-development PartnerInnovateRx LLC, founded in 2020 by 19 Blue Cross Blue Shield Plans and the Federal Employee Program in partnership with CivicaScript, aligns Plans around a shared goal of expanding access to affordable outpatient generic drugs and biosimilars.
• American Hospital Association (AHA) Center for Health InnovationminorGTM or Marketing PartnerCivica collaborates with the American Hospital Association's AHA Center for Health Innovation to address inquiries about the initiative; hospitals may call 800-242-4677 with questions.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Phlow Corporation: Civica's manufacturing partner for the Petersburg, VA sterile injectable facility under a $354M HHS/ASPR/BARDA contract. Operates in the same essential-medicines / domestic-generic-manufacturing space and shares the federal-aligned mission of strengthening U.S. drug supply.
• MAP International: A nonprofit global health organization that distributes essential medicines to vulnerable populations. Comparable as a 501(c)(3) with an essential-medicines access mission and pharmaceutical supply-chain capabilities.
• Direct Relief: A nonprofit humanitarian aid organization that distributes essential medications and medical supplies to U.S. safety-net providers and global health programs. Comparable in mission (essential medicines access), 501(c)(3) status, and B2B-style health-system partnerships.
• Civica, Inc. (Civica Rx): The parent operating nonprofit of the Civica Foundation; both entities share an identical mission to ensure essential generic medication availability and affordability. The Foundation is the 501(c)(3) fundraising arm while Civica, Inc. is the 501(c)(4) operating entity, making them inseparable counterparts.

Others

• Helmsley Charitable Trust: The $3.2M funder of the Rural Hospital Program and long-standing supporter of the Civica Foundation's insulin initiative. Comparable as a flagship U.S. healthcare philanthropist and donor peer that funds similar essential-medicines and rural-health initiatives.

Broad incumbents

• Blue Cross Blue Shield Association: Civica's partner through InnovateRx LLC (founded by 19 BCBS Plans and FEP). Comparable as a large payer ecosystem whose members benefit from CivicaScript outpatient pricing and whose plan capital underwrites Civica's nonprofit mission.
• AmerisourceBergen: Exclusive distribution partner for Civica and one of the 'Big 3' U.S. pharmaceutical distributors. Comparable as a healthcare distribution incumbent whose infrastructure Civica leverages for hospital reach; relevant as a benchmark for U.S. pharma supply-chain scale.
• McKesson: Largest U.S. pharmaceutical distributor and a critical link in the generic drug supply chain that Civica is built to circumvent for shortage drugs. Comparable as a broad incumbent whose pricing and supply practices are part of the shortage problem Civica addresses.

Regional players

• CalRx (California Health & Human Services Agency): California's state-branded biosimilar insulin program that co-distributes CivicaScript insulin under the CalRx brand. Comparable as a state-level affordability initiative aligned with Civica's mission.

Emerging players

• Biocon Biologics: Manufactures Civica's insulin glargine-yfgn product under its existing U.S. marketing approval and is a leading global biosimilar developer. Comparable in biosimilar insulin and outpatient-generics market overlap with CivicaScript.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/civicarx

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Civica Foundation